Rate of transfusion-associated adverse reactions by type U.S. 2023| ��ƽ��

Rate of blood transfusion-associated adverse reactions in the United States in 2021 and 2023, by type (per 100,000 components transfused)

Characteristic	2021	2023
Total number of reactions that required any diagnostic or therapeutic intervention*	273.8	312.3
Febrile, nonhemolytic transfusion reaction	113.3	131.3
Mild to moderate allergic reactions	71.4	82.2
Delayed serologic transfusion reaction	22.2	21.1
Transfusion-associated circulatory overload	14.7	19.3
Hypotensive transfusion reaction	7.8	9.5
Transfusion-associated dyspnea	5.5	7.4
Delayed hemolytic transfusion reaction	4.6	4.3
Severe allergic reactions	2.5	3.5
Reactions that were life threatening, requiring major medical intervention**	1	1.8
Acute hemolytic transfusion reaction (other antibodies)	1.4	1.2
Transfusion-related acute lung injury	1.1	1
Posttransfusion purpura	0.57	0.55
Acute hemolytic transfusion reaction (ABO)	0.37	0.46
Transfusion-transmitted bacterial infection (previously asked as posttransfusion sepsis)	0.34	0.25
Transfusion-associated graft-versus-host disease	-	0.04
Transfusion-transmitted viral infection	0.06	-
Transfusion-transmitted parasitic infection	0.02	-

Download

Source

Show detailed source information?

Already a member?

Sources

Release date

August 2025

More information

Region

United States

Survey time period

2021 and 2023

Method of interview

Online omnibus survey

Supplementary notes

Data is from the National Blood Collection and Utilization Survey (NBCUS).
* Diagnostic tests were defined as “any test to confirm a reaction occurred” and therapeutic intervention was defined as “intervention to treat a reaction (e.g., vasopressors, intubation, transfer to intensive care to prevent impairment, permanent damage, or death).
** For example, vasopressors, blood pressure support, intubation, or transfer to the intensive care unit.

Citation formats

In 2023, there were an estimated 312 blood transfusion-associated adverse reactions in the United States that required any diagnostic or therapeutic intervention per 100,000 components transfused. This graph shows the estimated rate of blood transfusion-associated adverse reactions in the United States in 2021 and 2023, by type, per 100,000 components transfused.